title: Flocor (CytRx Corp).
abstract: CytRx is developing Flocor, an amphipathic copolymer, as a potential treatment for acute sickle cell crisis and acute respiratory distress syndrome (ARDS)/acute lung injury 1. It is currently undergoing phase III clinical trials for the treatment of sickle cell crisis. Flocor has rheologic, cytoprotective, anti-adhesive and antithrombotic effects and has potential in the treatment of acute ischemic vascular disorders such as stroke and myocardial infarction (MI). A US NDA is planned for filing in late 1999 or 2000. Flocor is a highly purified form of the nonionic surfactant poloxamer 188, composed of a central block of hydrophobic poly(oxypropylene) units flanked by chains of hydrophilic poly(oxyethylene) units. It has superseded RheothRx (commercial grade poloxamer 188) because of its more favorable therapeutic index. The FDA has informed CytRx that data generated with RheothRx can be used to support an NDA for Flocor.
authors.affiliation: ALZA Corp, PO Box 10950, Palo Alto, CA 94303-0802, USA. nishit.modi@alza.com
authors.forename: N B
authors.initials: NB
authors.lastname: Modi